Prospective evaluation of the cardiovascular safety profile of abiraterone acetate (AA) in mCRPC patients (pts).

e16534Background: AA is a potent inhibitor of CYP17; common adverse events include fluid retention and hypertension. In COU-AA-301 study a 13.3% of cardiovascular (CV) toxicity was reported. The ai...